-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca To Host Conference Call To Discuss Preliminary Phase 1 Dose Escalation Data For Pan-RAS Molecular Glue ERAS-0015 In Patients With RAS-Mutant Solid Tumors On April 27

Benzinga·04/27/2026 12:34:44
Listen to the news

Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss preliminary Phase 1 dose escalation data for its potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors today, Monday, April 27, 2026, at 4:30 pm ET.